Abstract
Schizophrenia is a burdensome disease requiring consistent long-term treatment. Antipsychotic medication switching is common and nonadherence to oral antipsychotics is reported in up to two-thirds of patients with schizophrenia. Lumateperone is a mechanistically novel antipsychotic that was initially FDA-approved in December 2019 to treat adults with schizophrenia. In December 2021, lumateperone was approved to treat depressive episodes associated with bipolar I or bipolar II disorder, as monotherapy and as adjunctive therapy with lithium or valproate. This analysis evaluated real-world persistency of lumateperone 42 mg to treat schizophrenia using open claims databases.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
